Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VCYT vs FATE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VCYT Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

VCYT Overall Winner 6-Pillar Tally: VCYT 5 – 1 FATE Matrix Metrics: VCYT 8 – 2 FATE

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Fate Therapeutics, Inc. (FATE) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas FATE carries 43.0/100 (HOLD) at $1.14 (N/M Forward P/E, -2736.9% operating margin).

  • Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile FATE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 20.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VCYT vs FATE
VCYT NASDAQ Head-to-Head Winner
Veracyte, Inc.
Services-Medical Laboratories
$24.01
-1.32% 1D
Market Cap $2.0B
TTM Revenue $582M
Forward P/E 15.3x
Beta / 30D Vol 3.01β · 199% Vol
Unified Composite Score
49.1 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 57.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.8%), weak momentum, RSI 28
RSI-14: 27.8 · SMA20: $39.20 · SMA50: $41.79
FATE NASDAQ
Fate Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$1.14
-10.94% 1D
Market Cap $155.7M
TTM Revenue $4.8M
Forward P/E N/M
Beta / 30D Vol 2.16β · 104% Vol
Unified Composite Score
43.0 / 100 HOLD
Tech 25.0 Fund 47.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.8%), weak momentum, RSI 21
RSI-14: 20.9 · SMA20: $1.89 · SMA50: $2.13

6-Pillar Scorecard Institutional Category Breakdown (VCYT 5 – 1 FATE)

Columns: Metric · VCYT · FATE
1. Valuation Multiples VCYT
Forward P/E 15.3x N/M
Trailing P/E 15.8x N/M
PEG Ratio N/M N/M
EV / Revenue 3.1x 39.2x
2. Growth & Scale VCYT
Revenue Growth (YoY) +15.1% +9.2%
Earnings Growth (YoY) +58.3% +0.0%
TTM Revenue (USD) $582M $4.8M
Market Cap $2.0B $155.7M
3. Profitability & Quality VCYT
Gross Margin 74.2% N/A
Operating Margin 15.0% -2736.9%
Net Profit Margin 21.8% 0.0%
Return on Equity (ROE) 9.4% -67.8%
4. Balance Sheet & Cash Flow VCYT
Cash Generation (TTM) $162M -$107M
Cash Flow Margin 27.8% N/A
Net Cash / Leverage $159M Net Cash $31M Net Debt (0.56x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning FATE
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 197.3% (47th %ile) 169.0% (20th %ile)
Put/Call OI Skew 0.01x (Call-Skewed) 1.52x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat VCYT
OpEx & R&D Intensity 59.2% of Rev ($344M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VCYT (8) vs FATE (2)
Institutional Metric VCYT FATE Criterion Row Edge
Market Capitalization
Scale
$2.0B $155.7M Larger Scale VCYT
Trailing P/E Ratio
Valuation
15.8x N/M Lower Multiple VCYT
Forward P/E Ratio
Valuation
15.3x N/M Lower Multiple VCYT
Revenue Growth (YoY)
Growth
+15.1% +9.2% Higher Growth VCYT
Operating Margin (TTM)
Profitability
15.0% -2736.9% Higher Margin VCYT
Net Profit Margin
Profitability
21.8% 0.0% Higher Margin VCYT
Return on Equity (ROE)
Capital Efficiency
9.4% -67.8% Higher ROE VCYT
52-Week Range Position
Momentum
5% ($22–$61) 8% ($1–$3) Stronger Trend FATE
Beta / 30D Volatility
Risk Regime
3.01β · 199% Vol 2.16β · 104% Vol Lower Realized Risk FATE
Unified Institutional Score
Composite Signal
49.1 / 100 (HOLD) 43.0 / 100 (HOLD) Higher Composite VCYT
Trailing 12M Revenue (USD)
Operating Scale
$582M $4.8M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
74.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.1x EV/Rev N/M PEG · 39.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$162M ($159M Net Cash) -$107M ($31M Net Debt (0.56x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FATE +8.01 pp
VCYT: -44.32% · FATE: -36.31%
3M Horizon VCYT +14.49 pp
VCYT: -40.98% · FATE: -55.47%
6M Horizon FATE +8.04 pp
VCYT: -42.14% · FATE: -34.1%
1Y Horizon FATE +54.66 pp
VCYT: -39.78% · FATE: +14.88%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VCYT Revenue FATE Revenue VCYT Op. Margin FATE Op. Margin Margin Leader
FY2018 $90M $0M -24.2% -1415.4% VCYT
FY2019 $120M $10M -12.6% -943.1% VCYT
FY2020 $120M $30M -30.1% -407.5% VCYT
FY2021 $220M $60M -37.3% -388.6% VCYT
FY2022 $300M $100M -13.9% -320.2% VCYT
FY2023 $360M $60M -23.8% -299.9% VCYT
FY2024 $450M $10M 3.6% -1542.6% VCYT
FY2025 $520M $10M 11.2% -2222.4% VCYT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VCYT BREAKDOWN
99d in phase · OBV DISTRIBUTION
Current IV 197.3%
IV Percentile 47th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FATE BREAKDOWN
118d in phase · OBV DISTRIBUTION
Current IV 169.0%
IV Percentile 20th %ile
Put/Call OI Skew 1.52x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact FATE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VCYT Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $2.0B market capitalization and 15.0% operating margin.
OpEx & R&D Reinvestment 59.2% of Rev ($344M)
90D Engineering Disclosures 0 Published
FATE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $155.7M market capitalization and -2736.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VCYT vs FATE Key Questions & Quantitative Answers

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Fate Therapeutics, Inc. (FATE) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas FATE carries 43.0/100 (HOLD) at $1.14 (N/M Forward P/E, -2736.9% operating margin). Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile FATE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 20.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VCYT leads the Growth & Scale pillar: VCYT posts +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin), compared with FATE at +9.2% YoY revenue growth and +0.0% YoY earnings growth on $4.8M TTM revenue (N/A gross margin, -2736.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VCYT cumulative revenue shifted +477.8% while FATE shifted +0.0%. In operating R&D and SG&A reinvestment, VCYT deploys 59.2% of Rev ($344M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FATE.

VCYT screens cheaper on headline valuation multiples. VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin), whereas FATE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 39.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VCYT (9.4% ROE) versus FATE (-67.8% ROE) capital efficiency.

In options market volatility and institutional positioning, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 199% Vol realized risk). By comparison, FATE carries 169.0% implied volatility (20th %ile, Compressed (<25th %ile)), a 1.52x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.16β · 104% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.